Knoll Capital Management LLC lifted its position in shares of Entera Bio Ltd. (NASDAQ:ENTX - Free Report) by 51.5% during the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 5,881,879 shares of the company's stock after acquiring an additional 2,000,000 shares during the quarter. Entera Bio accounts for approximately 8.0% of Knoll Capital Management LLC's investment portfolio, making the stock its 3rd biggest holding. Knoll Capital Management LLC owned approximately 16.44% of Entera Bio worth $12,470,000 at the end of the most recent quarter.
Separately, Perigon Wealth Management LLC purchased a new stake in Entera Bio in the 4th quarter worth $325,000. 14.11% of the stock is currently owned by hedge funds and other institutional investors.
Entera Bio Price Performance
ENTX stock traded down $0.01 during trading on Monday, hitting $1.95. The stock had a trading volume of 96,107 shares, compared to its average volume of 70,814. Entera Bio Ltd. has a twelve month low of $1.41 and a twelve month high of $2.79. The company's 50-day moving average price is $1.93 and its two-hundred day moving average price is $2.04. The stock has a market capitalization of $88.63 million, a P/E ratio of -7.50 and a beta of 1.51.
Entera Bio (NASDAQ:ENTX - Get Free Report) last released its earnings results on Friday, May 9th. The company reported ($0.06) earnings per share for the quarter, beating the consensus estimate of ($0.07) by $0.01. The firm had revenue of $0.04 million during the quarter. As a group, sell-side analysts expect that Entera Bio Ltd. will post -0.28 EPS for the current fiscal year.
Analyst Ratings Changes
Separately, HC Wainwright reaffirmed a "buy" rating and set a $10.00 price objective on shares of Entera Bio in a report on Tuesday, March 18th.
View Our Latest Stock Report on Entera Bio
Entera Bio Company Profile
(
Free Report)
Entera Bio Ltd., a clinical-stage company, focuses on the development and commercialization of orally delivered peptide and protein therapeutics for unmet medical needs. The company's product candidates include the EB612, which is in Phase II clinical trials for the treatment of hypoparathyroidism; and EB613 that has completed Phase II clinical trials for the treatment of osteoporosis, as well as is in Phase I clinical trials for the treatment of stress fractures.
Featured Articles
Before you consider Entera Bio, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Entera Bio wasn't on the list.
While Entera Bio currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Market downturns give many investors pause, and for good reason. Wondering how to offset this risk? Enter your email address to learn more about using beta to protect your portfolio.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
